셀트리온 제약

1) Adult Crohn's disease

- Moderate to severe active Crohn's disease that does not respond to treatment with corticosteroids or immunosuppressants, is intolerant to them, or is contraindicated to these treatments

- Active fistulous Crohn's disease that does not respond to conventional treatments such as antibiotics, drainage methods, and immunosuppressive therapy.

2) Crohn's disease in children and adolescents (6-17 years old)

Severely active Crohn's disease in children and adolescents (6-17 years) who have not responded to, are intolerant to, or are contraindicated in conventional treatment with corticosteroids, immunomodulators, or primary nutritional therapy. This drug has been studied only in combination with conventional immunosuppressive therapy.

3) Ankylosing spondylitis with severe inflammatory symptoms and elevated serum markers associated with inflammation that do not respond adequately to conventional treatment

4) Moderate to severe ulcerative colitis that does not respond adequately to or is intolerant to common treatment drugs such as corticosteroids, 6-mercaptopurine, or azathioprine, or for which these drugs are contraindicated

5) Ulcerative colitis in children and adolescents (6-17 years old)

Moderate to severe ulcerative colitis in children and adolescents (6-17 years) who have not responded adequately to, are intolerant to, or are contraindicated in the treatment of common medications such as corticosteroids, 6-mercaptopurine, or azathioprine

6) Improvement of symptoms, signs and physical functions in patients with rheumatoid arthritis

- Active arthritis with inadequate response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate

- Severe, active, progressive arthritis not previously treated with methotrexate or other DMARDs. In this group of patients, a decrease in the rate of progression of joint damage as assessed by X-ray measurements was observed.

7) Active progressive psoriatic arthritis in adults who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs)

- This drug can be administered in combination with methotrexate.

- This drug can be administered alone to patients who are intolerant to methotrexate or for whom methotrexate is contraindicated.

The drug has been shown to improve physical function in patients with psoriatic arthritis and to slow the progression of peripheral joint damage as assessed by X-ray examination in patients with symmetric polyarthritis.

8) Moderate to severe plaque psoriasis in adults who have not responded to, are contraindicated in, or are intolerant to systemic therapy, including cyclosporine, methotrexate, or PUVA.

9) Behcet's enteritis

Behcet's enteritis that does not respond adequately to conventional treatments such as corticosteroids or immunosuppressants, is intolerant, or is contraindicated in these treatments

Infliximab 100mg